Menu UF Health Home Menu
 

Our Most Recent Publications


  1. Horne, P & Mills, R.  Implications of the 2012 Centers for Disease Control and Prevention (CDC) guidelines for screening hepatitis C infection in the United States.  Practical Gastroenterology.  2013 Feb Vol. XXXVII, No. 2.
  2. CC genotype donors for the Interleukin-28B single nucleotide polymorphism are Associated with Better Outcomes in Hepatitis C after Liver Transplant. Firpi RJ, Dong H, Clark VC, Soldevila-Pico C, Morelli G, Cabrera R, Norkina O, Shuster JJ, Nelson DR, Liu C. Liver Int. 2012 Oct 29. doi: 10.1111/liv.12013. [Epub ahead of print]
  3. The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma. Cabrera R, Limaye AR, Horne P, Mills R, Soldevila-Pico C, Clark V, Morelli G, Firpi R, Nelson DR. Aliment Pharmacol Ther. 2013 Jan;37(1):91-7.
  4. Neutrophil-lymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma. Limaye AR, Clark V, Soldevila-Pico C, Morelli G, Suman A, Firpi R, Nelson DR, Cabrera R. Hepatol Res. 2012 Nov 30. doi: 10.1111/hepr.12019. [Epub ahead of print]
  5. Liver Test Results Do Not Identify Liver Disease in Adults With Αlpha(1)-Antitrypsin Deficiency. Clark VC, Dhanasekaran R, Brantly M, Rouhani F, Schreck P, Nelson DR. Clin Gastroenterol Hepatol. 2012 Jul 24.
  6. Unexpected Maintenance of Hepatitis C Viral Diversity following Liver Transplantation. Gray RR, Strickland SL, Veras NM, Goodenow MM, Pybus OG, Lemon SM, Fried MW, Nelson DR, Salemi M. J Virol. 2012 Aug;86(16):8432-9. Epub 2012 May 23.
  7. Impact of Transarterial Therapy in Hepatitis C-Related Hepatocellular Carcinoma on Long-term Outcomes After Liver Transplantation. Cabrera R, Dhanasekaran R, Caridi J, Clark V, Morelli G, Soldevila-Pico C, Magglioca J, Nelson D, Firpi RJ. Am J Clin Oncol. 2012 Aug;35(4):345-50. PMID:21552101
  8. Diagnosis and management of patients with α1-antitrypsin (A1AT) deficiency. Nelson DR, Teckman J, Di Bisceglie AM, Brenner DA. Clin Gastroenterol Hepatol. 2012 Jun;10(6):575-80.
  9. Genome sequence of the model medicinal mushroom Ganoderma lucidum. Chen S, Xu J, Liu C, Zhu Y, Nelson DR, Zhou S, Li C, Wang L, Guo X, Sun Y, Luo H, Li Y, Song J, Henrissat B, Levasseur A, Qian J, Li J, Luo X, Shi L, He L, Xiang L, Xu X, Niu Y, Li Q, Han MV, Yan H, Zhang J, Chen H, Lv A, Wang Z, Liu M, Schwartz DC, Sun C. Nat Commun. 2012 Jun 26;3:913.
  10. Safety of cardiac surgery for patients with cirrhosis and Child-Pugh scores less than 8. Macaron C, Hanouneh IA, Suman A, Lopez R, Johnston D, Carey WW. Clin Gastroenterol Hepatol. 2012 May;10(5):535-9.
  11. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Abdelmalek MF, Humar A, Stickel F, Andreone P, Pascher A, Barroso E, Neff GW, Ranjan D, Toselli LT, Gane EJ, Scarola J, Alberts RG, Maller ES, Lo CM; Sirolimus Liver Conversion Trial Study Group. Am J Transplant. 2012 Mar;12(3):694-705. PMID: 22233522
  12. Trends in the prevalence of thrombocytopenia among individuals infected with hepatitis C virus in the United States, 1999-2008. Kauf TL, Nelson DR, Schelfhout J, Delaney JA, Wang PF. BMC Res Notes. 2012 Mar 13;5:142.
  13. The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C. Clark V, Nelson DR. Liver Int. 2012 Feb;32 Suppl 1:103-7.
  14. Randomized, controlled trial of standard, large-capacity versus jumbo biopsy forceps for polypectomy of small, sessile, colorectal polyps. Draganov PV, Chang MN, Alkhasawneh A, Dixon LR, Lieb J, Moshiree B, Polyak S, Sultan S, Collins D, Suman A, Valentine JF, Wagh MS, Habashi SL, Forsmark CE. Gastrointest Endosc. 2012 Jan;75(1):118-26.
  15. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Thompson AJ, Patel K, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Rustgi VK, Flisiak R, Pianko S, Diago M, Arora S, Foster GR, Torbenson M, Benhamou Y, Nelson DR, Sulkowski MS, Zeuzem S, Pulkstenis E, Subramanian GM, McHutchison JG; ACHIEVE-1 and ACHIEVE-2/3 Study Teams. Gut. 2012 Jan;61(1):128-34.
  16. University of Florida Clinical and Translational Science Institute: transformation and translation in personalized medicine. Nelson DR, Conlon M, Baralt C, Johnson JA, Clare-Salzler MJ, Rawley-Payne M. Clin Transl Sci. 2011 Dec;4(6):400-2.
  17. Management of recurrent hepatitis C infection after liver transplantation. Limaye AR, Firpi RJ. Clin Liver Dis. 2011 Nov;15(4):845-58.
  18. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases. Hepatology. 2011 Oct;54(4):1433-44.
  19. Response-guided telaprevir combination treatment for hepatitis C virus infection. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F; ILLUMINATE Study Team. N Engl J Med. 2011 Sep 15;365(11):1014-24.
  20. Expression of an IRF-3 fusion protein and mouse estrogen receptor, inhibits hepatitis C viral replication in RIG-I-deficient Huh 7.5 cells. Yao L, Yan X, Dong H, Nelson DR, Liu C, Li X. Virol J. 2011 Sep 21;8:445.
  21. Is Model for End-Stage Liver Disease score associated with quality of life after liver transplantation? Rodrigue JR, Nelson DR, Reed AI, Hanto DW, Curry MP. Prog Transplant. 2011 Sep;21(3):207-14.
  22. Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. Shah SR, Patel K, Marcellin P, Foster GR, Manns M, Kottilil S, Healey L, Pulkstenis E, Subramanian GM, McHutchison JG, Sulkowski MS, Zeuzem S, Nelson DR. Clin Gastroenterol Hepatol. 2011 Aug;9(8):688-93.
  23. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Cabrera R, Pannu DS, Caridi J, Firpi RJ, Soldevila-Pico C, Morelli G, Clark V, Suman A, George TJ Jr, Nelson DR.  Aliment Pharmacol Ther. 2011 Jul;34(2):205-13. PMID:21605146
  24. Racial differences in hepatitis C treatment eligibility. Melia MT, Muir AJ, McCone J, Shiffman ML, King JW, Herrine SK, Galler GW, Bloomer JR, Nunes FA, Brown KA, Mullen KD, Ravendhran N, Ghalib RH, Boparai N, Jiang R, Noviello S, Brass CA, Albrecht JK, McHutchison JG, Sulkowski MS; IDEAL Study Team. Hepatology. 2011 Jul;54(1):70-8. PMID:21488082
  25. Boceprevir for chronic HCV genotype 1 infection. Limaye AR, Draganov PV, Cabrera R. N Engl J Med. 2011 Jul 14;365(2):176; author reply 177-8. PMID:21751914
  26. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Bzowej N, Nelson DR, Terrault NA, Everson GT, Teng LL, Prabhakar A, Charlton MR; PHOENIX Study Group. Liver Transpl. 2011 May;17(5):528-38.
  27. Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study. Han SH, Reddy KR, Keeffe EB, Soldevila-Pico C, Gish R, Chung RT, Degertekin B, Lok A; NIH HBV OLT Study Group. Clin Transplant. 2011 Mar-Apr;25(2):E152-62.
  28. Natural history of small duct primary sclerosing cholangitis: a case series with review of the literature. Singal AK, Stanca CM, Clark V, Dixon L, Levy C, Odin JA, Fiel MI, Friedman SL, Bach N. Hepatol Int. 2011 Sep;5(3):808-13. Epub 2011 Mar 11.
  29. Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. Cao M, Xu Y, Youn JI, Cabrera R, Zhang X, Gabrilovich D, Nelson DR, Liu C. Lab Invest. 2011 Apr;91(4):598-608. Epub 2011 Feb 14. PMID:21321535
  30. Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Nelson DR, Zeuzem S, Andreone P, Ferenci P, Herring R, Jensen DM, Marcellin P, Pockros PJ, Rodríguez-Torres M, Rossaro L, Rustgi VK, Sepe T, Sulkowski M, Thomason IR, Yoshida EM, Chan A, Hill G. Ann Hepatol. 2012 Jan-Feb;11(1):15-31.
  31. Reactive oxygen species is essential for cycloheximide to sensitize lexatumumab-induced apoptosis in hepatocellular carcinoma cells. Zhao X, Cao M, Liu JJ, Zhu H, Nelson DR, Liu C. PLoS One. 2011 Feb 10;6(2):e16966.
  32. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Levy C, Peter JA, Nelson DR, Keach J, Petz J, Cabrera R, Clark V, Firpi RJ, Morelli G, Soldevila-Pico C, Lindor K. Aliment Pharmacol Ther. 2011 Jan;33(2):235-42. PMID:21083674
  33. Different radiosensitivity of CD4(+)CD25(+) regulatory T cells and effector T cells to low dose gamma irradiation in vitro. Cao M, Cabrera R, Xu Y, Liu C, Nelson D. Int J Radiat Biol. 2011 Jan;87(1):71-80. PMID:20958220
  34. Characterization of HCV interactions with Toll-like receptors and RIG-I in liver cells. Eksioglu EA, Zhu H, Bayouth L, Bess J, Liu HY, Nelson DR, Liu C. PLoS One. 2011;6(6):e21186.
  35. The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients. Nelson DR. Liver Int. 2011 Jan;31 Suppl 1:53-7.